Results 171 to 180 of about 1,551 (185)

Efficacy and safety of givosiran for acute hepatic porphyria: 24‐month interim analysis of the randomized phase 3 ENVISION study

Liver International, 2022
Paolo Ventura, Laurent Gouya, Manisha Balwani   +2 more
exaly  

Homocysteine elevation in givosiran treatment: Suggested ALAS1 siRNA effect on cystathionine beta‐synthase

Journal of Internal Medicine, 2021
Daphne Vassiliou, Eliane Sardh
openaire   +2 more sources

Givosiran, a novel treatment for acute hepatic porphyrias

Expert Review of Precision Medicine and Drug Development, 2021
Manish Thapar, Herbert L Bonkovsky
exaly  

A Drug‐Drug Interaction Study Evaluating the Effect of Givosiran, a Small Interfering Ribonucleic Acid, on Cytochrome P450 Activity in the Liver

Clinical Pharmacology and Therapeutics, 2021
Daphne Vassiliou, Eliane Sardh, Pauline Harper   +2 more
exaly  

Summary of opinion: Givlaari,givosiran

Case Medical Research, 2020
openaire   +1 more source

FDA approves givosiran for acute hepatic porphyria

Case Medical Research, 2019
openaire   +2 more sources

Pharmacokinetics and Pharmacodynamics of the Small Interfering Ribonucleic Acid, Givosiran, in Patients With Acute Hepatic Porphyria

Clinical Pharmacology and Therapeutics, 2020
Sagar Agarwal
exaly  

Personalized dosage of Givosiran in acute intermittent porphyria

Medicina Clínica (English Edition)
Manuel, Garrido Montes, Roberto, Pertusa Mataix, Jose Salvador, Garcia Morillo   +2 more
openaire   +2 more sources

Givosiran for Acute Intermittent Porphyria. Reply.

The New England journal of medicine, 2020
Manisha, Balwani, Eliane, Sardh, Laurent, Gouya   +2 more
openaire   +1 more source

Givosiran. ALAS1 expression inhibitor, Treatment of acute porphyria

Drugs of the Future, 2020
openaire   +1 more source